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ABSTRACT   
Congenital cytomegalovirus (CMV) infection
cause both, immediate and long term health problems in infants. These include
as hearing loss, microcephaly, jaundice, hepatosplenomegaly and seizures. 
infection can cause the death of an unborn baby and loss of pregnancy.
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1. Introduction  
Human Herpes Virus 5 or Cytomegalovirus (CMV) is encapsulated, double
genome of 235 kb, which belongs to 
cause of congenital infections and birth dysfunctions, known to affect 0.5
infects and replicates in several cell types, including epithelial glandular and mucosal cells, smooth muscle 
cells, fibroblasts, macrophages, dendritic cells, hepatocytes
of CMV occurs by direct contact with infected secretions (blood, saliva, breast milk
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From October 2017 to November 2019, Eurofarm Center laboratory based in Sarajevo has recorded an 
increasing number of infants experiencing symptoms of congenital CMV infection. Similarly, the increscent 
incidence of congenitally infected newborns has been observed as a global problem [8]. Recent studies have 
shown improvements in the diagnostics, treatment, and prevention of CMV infection in pregnancy, ensuring 
better outcomes for the congenitally infected infants [9]–[11].  However, despite the tremendous research 
performed in the field of CMV pathogenesis, the consequences of CMV infection are still not familiar to the 
general public. Therefore, this study aims to elucidate the sensitivity and importance of urine samples for the 
detection of CMV DNA in infants as well as to reflect the importance of qRT-PCR as a molecular technique 
for non-invasive diagnostics of CMV infection of infants. This study demonstrates the fast and non-invasive 
testing of infants with accurate results, with the emphasis on the choice between urine and blood samples.  
2. Materials and methods 
Samples for this study were obtained from infants and expectant mothers inhabiting the Sarajevo Canton. 
Collected peripheral whole blood and urine samples were analyzed in the period from October 2017 to 
November 2019 in Eurofarm Center laboratory, Sarajevo.  
The study was performed on a cohort of 72 patients aged from infancy up to 44 years of life. The descriptive 
analysis of patients is shown in Table 1. Among the 72 patients tested for the presence of CMV DNA, 41 are 
female patients (56.9%) and 31 are male patients (43.1%). Infants make 41.6% of total patients analyzed. 
Furthermore, the study included patients up to 13 years (19.4%), potential and expectant mothers (29.3%), 
while 9.7% of patients did not provide their birth year before the CMV DNA screening.  
 
 




n % P value 
Age range (years)    
0-2 30 41.6 
>0.05 >2 35 48.6 
NA 7 9.7 
Gender    
Male 31 56.9 
>0.05 
Female 41 43.1 
 
 
2.1. Sample collection 
Peripheral whole blood was drawn and collected into the BD Vacutainer® with EDTA anticoagulant. 
Following the collection of peripheral whole blood, a blood sample was left for 10 minutes to cool down and 
then stored in the fridge at 4°C until the DNA extraction was performed. Urine samples were collected into 
sterile plastic bags or the collection tubes. Following the collection, urine was transferred into sterile falcon 
tubes and centrifuged in a clinical centrifuge for 10 minutes at 45000 rpm. Similarly, urine was stored in the 
fridge at 4°C until the DNA extraction was performed. In total, 122 samples were analyzed. Patient’s samples 
were analyzed according to the principles of the Declaration of Helsinki. 
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2.2. DNA extraction 
Spin column-based DNA extraction from urine and peripheral whole blood was performed in Fume hood-
BIOBASE (USA) by “Invitrogen - PureLink® Genomic DNA Purification Kit K1820-02” (InvitrogenTM, 
2007). Genomic DNA was stored at +4°C prior to the qRT-PCR analysis. Following the qRT-PCR analysis, 
all DNA extracts were stored at -20°C. 
2.3. DNA quantification 
The concentration and purity of extracted genomic DNA were assessed by μDropTM plate (ThermoFisher 
Scientific, USA), MultiscanTM GO microplate spectrophotometer (ThermoFisher Scientific, USA) and the 
accompanying SkanIt Software. Samples were analyzed in triplicates, blanked against 10 mM Tris-HCl, and 
the mean values were calculated based on data obtained. 
2.4. CMV qRT-PCR 
For the purpose of CMV DNA detection, qRT-PCR analysis was performed by PrimerDesign Genesig Kit for 
Human Herpes Virus 5 (Primerdesign TM, 2018). The target sequence was glycoprotein B (gB). qRT-PCR 
reaction setup was performed in DNA free zone PCR workstation-UVC/T-AR (BioSan, Latvia). The 
following components were used in all qRT-PCR analyses: 10μl of PrecisionPLUS 2X qPCR Master Mix 
(containing Taq DNA polymerase, reaction buffer, MgCl2, and dNTPs), 4μl of RNase/DNase free water, and 
1μl of CMV primer/probe mix. Herein, 5μl of extracted DNA was added to the test tubes, while 5μl of CMV 
DNA was added to the positive control tube (Primerdesign TM, 2018). Once set, 96-well plate containing test 
and control tubes were centrifuged at 900 rpm for 2 minutes. qRT-PCR analyses were run in the Thermal 
Cycler-Quant studio 5, (Thermo Fisher, Singapore) with following amplification conditions: hold stage at 
95°C for 2 minutes, and PCR stage which includes DNA denaturation step at 95°C for 10 seconds and data 
collection step at 60°C for 1 minute.  
PCR stage was repeated in 50 cycles. The collection of fluorogenic data through the FAM channel occurred 
during the data collection step. Each tested sample and positive control were assigned CMV target during the 
PCR analysis. Likewise, every analysis was performed without passive reference. Upon analysis completion, 
cycle threshold (CT) values of amplified samples were compared to the CT values of standards. Thus, the 
number of CMV DNA copies/ml of the sample was calculated. 
2.5. Statistical analysis 
Results were statistically evaluated using GraphPad Prism version 8.0.1 for Windows, GraphPad Software, La 
Jolla California USA. Results are considered significant when P<0.05. 
 
 
3. Results and discussion 
 
3.1. DNA quantification 
Results demonstrated in this subsection correspond to 17 pooled patients screened positive for CMV DNA. 
Whole blood samples yielded more DNA (in μg/ml) compared to the urine sample, which was consistent with 
our expectations. As shown in Figure 1, the concentrations of DNA extracted from blood samples ranged from 
12.8 to 53.6 μg/ml, with a mean value of 33.2 μg/ml. The concentrations of DNA extracted from urine 
samples ranged from 2.5 to 7.6 μg/ml, with a mean value of 5.05 μg/ml. Statistical significance of higher 




Results shown in Figure 2 demonstrate the analysis of DNA purity. Purities of extracted DNA from blood 
samples ranged from 1.7 to 2.7, with a mean value of 2.11, while purities of urine’s DNA extract ranged from 
1.2 to 3.3, with a mean value of 1.77. Regarding urine samples, results 
sufficiently pure for further testing, particularly considering the heterogeneity of urine samples. Statistical 
analysis of results related to the purity of extracted geno
statistical significance (P=0.211).  
 
Figure 2. Measurement of the genomic DNA (260nm and 280nm)
3.2. qRT-PCR analysis  
Results of qRT-PCR performed on blood and urine samples are show
screened, results have shown 45 positive (
DNA. At the beginning of the study, 31 (25.4%) samples were analyzed but their sample type was not 
recorded and therefore not included in overall sample type distribution analysis.
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Among the 122 samples 
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Figure 3. Number of CMV DNA copies/ml detected in blood and urine samples 
 
All 45 samples screened as positive for CMV DNA were collected from infants. The age span of the patient’s 
samples screened as negative vary, but women of child-bearing age predominate. When CMV DNA positive 
samples were classified by the source of extracted DNA, preferable body fluid for CMV shedding becomes 
clarified. Out of 45 positive samples, CMV DNA was found in 27 urine, and 18 blood samples. 
 
Furthermore, the difference between the number of CMV DNA copies detected per milliliter of urine and 
blood samples are demonstrated in Figure 4. Analyzed samples are independent of each other. Data obtained 
may suggest that in infants CMV is rather shed in urine (Figure 4A) compared to blood (Figure 4B), as 
indicated by a higher mean of CMV DNA copies/ml of sample. Statistical analysis for 27 urine and 18 blood 
samples has shown P= 0.4544, meaning that a higher number of CMV DNA copies amplified from DNA 
extracted from urine samples is not statistically significant. Non-significant results may be explained by an 
unequal number of blood and urine samples included in statistical analysis. Thus, significant results may be 
obtained in a larger cohort of patients with two sets of equal sample numbers.  
 
 
Figure 4. Number of CMV DNA copies detected in urine (A) and blood (B) samples 
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Results shown in Figure 5 demonstrate the difference between the detection of CMV DNA in urine and blood 
samples of infants that have performed simultaneous screening for CMV DNA. Patients CMV-31, CMV-32, 
and CMV-69 have been subjected to the multiple analyses throughout the study, primarily due to the lack of 
the therapy response. In all three patients, discrepancies between the number of CMV DNA copies/ml of 
blood and urine samples can be observed. In the case of CMV-31,a higher number of CMV DNA copies/ml 
was detected in urine when compared to the blood sample. However, for CMV-32 and CMV-69 qRT-PCR 
screening has detected no CMV DNA in blood, while in urine analysis has detected 2x106and 2x103CMV 
DNA copies/ml of sample, respectively. This analysis suggests that urine samplesmay be more sensitive for 
CMV DNA amplification in infants and as such should be suggested as a sample of choice for confirmation of 
CMV infection in infants. Likewise, results shown in Figure 5 indicate that solely blood or solely urine sample 
may not be sufficiently reliable for accurate diagnosis of CMV infection in infants. Thus, the evaluation of 










Six infants were included in the follow-up study, and the results of their individual analyses are shown in 
Figure 6. Follow-up analyses were performed every three to four weeks. All patients included in the follow-up 
study were given oral antiviral therapy Valganciclovir. Valganciclovir efficiently inhibits CMV DNA 
polymerase [12], as shown by a gradual decrease of CMV DNA copies in patients CMV-32 and CMV-39. 
Such decreasing trend cannot be observed in patients CMV-18, CMV-31, CMV-36, and CMV-44 which have 
been associated with more prominent symptoms and multiple complications.  
Interestingly, CMV DNA screening of the patient CMV-36 has shown complete drug unresponsiveness as 
indicated by more than 2x103CMV DNA copies/ml of sample on last four follow-up analyses. Moreover, a 
higher number of CMV DNA copies can be observed in urine when compared to blood samples, as shown in 
Figure 4C-F. 
 
Since this study was performed as a retrospective cohort study, there was no opportunity to select the type of 
patient sample for analysis. However, exactly this issue has clarified the differences between urine and blood 
samples regarding the amplification of CMV DNA. 
 





Figure 6. The number of CMV DNA copies detected in patients included in the follow-up study 
 
4. Conclusion 
This study aimed to elucidate the sensitivity and importance of urine samples for the detection of CMV DNA 
in infants. Quantification of extracted DNA has demonstrated that DNA yield from urine samples is sufficient 
for the qRT-PCR analysis (>1 μg/ml). Furthermore, the sensitivity of the urine sample for the detection of 
CMV DNA has been confirmed by qRT-PCR amplification. As demonstrated by simultaneous blood and 
urine analysis and follow-up study, urine samples have been confirmed as those with higher CMV DNA 
amplification. Therefore, great care should be taken when making a selection for an infant’s sample type for 
CMV DNA screening. Having said this, one may propose that in infants, CMV-related genitourinary 
infections are more common, when compared to systemic infections. Also, the lower number of CMV DNA 
copies detected in blood samples may be explained by the assumption that patients did not develop viremia at 
the time of the sample collection. 
Despite the limitations of sample type selection for qRT-PCR analysis, this retrospective cohort study has 
confirmed that urine is a sensitive and preferable sample for thefast, non-invasive, and accurate screening of 
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CMV DNA of infants. Demonstrated results may prompt the classification of CMV screening among one of 
the first-trimester pregnancy screening tests, which would serve as one of the means to reduce the incidence of 
CMV infection in Sarajevo Canton. 
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